Skip to main content

Table 1 Demographic and baseline data and clinical characteristics (cross-sectional population and longitudinal population sets)

From: Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study

Characteristic Cross-sectional population
N = 357
Longitudinal population
N = 123
Female 232 (65.0) 76 (61.8)
Caucasian 340 (95.2) 117 (95.1)
Age, years (mean ± SD) 50.5 ± 15.5 52.7 ± 13.6
At least one comorbidity 208 (58.3) 77 (62.6)
Asthma duration, years (mean ± SD)a 18.4 ± 14.9 19.8 ± 14.5
Age at diagnosis, years (mean ± SD)a 32.1 ± 17.4 32.7 ± 15.8
Number of asthma exacerbations during the 12 months before enrolmentb 3.6 ± 4.2 4.6 ± 4.1
ACQ total scoresc 2.4 ± 1.2 2.9 ± 1.1
Smoking history
 Non-smoker 265 (74.2) 90 (73.2)
 Former smoker 67 (18.8) 27 (22.0)
 Current smoker 25 (7.0) 6 (4.9)
FEV1 (L)d 2.0 ± 0.8 1.7 ± 0.7
IgE serum level, IU/mL, (mean ± SD)e 434.8 ± 556.4 409.3 ± 394.1
At least one concomitant pharmacological treatment for respiratory disease 122 (99.2)
Corticosteroids for systemic use 50 (40.7)
  1. Data are presented as n (%), unless otherwise specified
  2. an = 347 in cross-sectional population and n = 119 in longitudinal population
  3. bn = 330 in cross-sectional population and n = 119 in longitudinal population
  4. cn = 339 in cross-sectional population and n = 96 in longitudinal population
  5. dn = 342 in cross-sectional population and n = 121 in longitudinal population (assessed at baseline or within 3 months before enrolment)
  6. en = 252 in cross-sectional population and n = 121 in longitudinal population (assessed at baseline or within 3 months before enrolment)
  7. ACQ asthma control questionnaire, FEV1 forced expiratory volume in one second, IgE immunoglobulin E, SD standard deviation